Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens | Zendy

Huib A.A.M. van Vliet | Zendy; Marijke Frölich | Zendy; M. Christella | Zendy; Stella Thomassen | Zendy; Carine J.M. Doggen | Zendy; Frits R. Rosendaal | Zendy; Jan Rosing | Zendy; Frans M. Helmerhorst | Zendy

Open Access

Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens

Author(s) -

Huib A.A.M. van Vliet,

Marijke Frölich,

M. Christella,

Stella Thomassen,

Carine J.M. Doggen,

Frits R. Rosendaal,

Jan Rosing,

Frans M. Helmerhorst

Publication year - 2004

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/deh612

Subject(s) - gestodene , desogestrel , medicine , sex hormone binding globulin , levonorgestrel , estrogen , cyproterone acetate , endocrinology , population , pill , progestin , progestogen , gynecology , physiology , family planning , hormone , pharmacology , androgen , environmental health , research methodology

Epidemiological studies have shown that both the estrogen dose and progestogen type of oral contraceptives contribute to the increased risk of thrombosis in oral contraceptive users. Thrombin generation-based activated protein C (APC) sensitivity is a global test for the net prothrombotic effect of oral contraceptives and predicts the thrombotic risk. Our objective was to test the usefulness of sex hormone-binding globulin (SHBG) as a marker for the thrombotic risk of an oral contraceptive.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research